Compare Elastic NV (ESTC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Viatris Inc — how do they compare? Elastic NV trades at $76.35 (market cap $7.94B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.4× Elastic NV's market cap, and Viatris Inc pays a 2.95% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | VTRS | |
|---|---|---|
Market Cap | $7.94B | $18.69B |
Sector | Technology | Health |
52-Week High | $94.47 | $17.86 |
52-Week Low | $43.30 | $9.49 |
Enterprise Value | $7.16B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $76.64, up 0.42% today, with a bullish technical outlook as it trades above key moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.61 exceeding the $0.561 estimate. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Revenue growth is robust, projected to rise from $1.48B in 2025 to $1.7B in 2026, while net income is expected to turn positive at $368M.
The stock offers growth potential driven by AI partnerships and market leadership, but faces risks from high valuation multiples like a P/E of 22.26 and EV/EBITDA of 206.43. Analyst consensus is bullish with a $74.21 price target and no sell ratings, though RSI levels indicate overbought conditions. Key risks include competitive pressures and reliance on tech sector demand.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
